Background/purpose Treatment of chronic hepatitis C (CHC) has entered a new era since
the introduction of direct-acting antiviral agents (DAAs). Numerous clinical trials have shown …

Introduction The current model of medical knowledge production, transfer, and application
suffers from serious shortcomings. Learning health systems (LHS) have recently emerged as …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has
been linked to improved patient outcomes. In the era of direct‐acting antivirals (DAA s), HCV …

The aim of the study is to analyze treatments available for patients infected with genotype
(G) 3 hepatitis C virus (HCV) in Poland at the beginning of the interferon (IFN)-free era and …

Background Opioid agonist treatment (OAT) supports adherence in medication regimens for
other concurrent conditions. However, sparse evidence is available on its effect on …

This study aimed to investigate the efficacy and safety of sofosbuvir‐based therapies for the
treatment of cirrhosis from hepatitis C virus (HCV) genotype 2 infection. Data of all …

Abstract The Side Effects of Drugs Annuals is a series of volumes in which the adverse
effects of drugs and adverse reactions to them are surveyed. This review of the January …

Background: With the availability of direct acting antiviral treatment for hepatitis C (HCV), HIV
and HCV co-infected patients show comparable treatment responses to HCV-monoinfected …

Objective: Sofosbuvir and ribavirin represented until recently the standard of care in hepatitis
C virus genotype 2 cirrhotic patients. In registration trials, 12-16 week durations were …

Background: In the interferon era, patients with HCV-related cirrhosis were considered hard
to treat due to contraindications to therapy, safety issues, and poor response. Objectives: We …